- 1A-116
-
- $46.00
-
2026-04-20
- CAS:1430208-73-3
- Purity: 99.71%
- Supply Ability: 10g
- 1A-116
-
- $46.00
-
2026-04-20
- CAS:1430208-73-3
- Purity: 99.71%
- Supply Ability: 10g
|
| Product Name: | 1A-116 | | Synonyms: | 1A-116;1A-116; 1A 116; 1A116;1430208-73-3;Guanidine, N-(3,5-dimethylphenyl)-N'-[2-(trifluoromethyl)phenyl]-;TIAM1,inhibit,1A 116,Ras,Rho GTPases,EGF,Apoptosis,1A-116,circadian rhythms,1A116,Inhibitor;1-(3,5-Dimethylphenyl)-3-(2-(trifluoromethyl)phenyl)guanidine , 1A-116;1-(3,5-Dimethylphenyl)-3-(2-(trifluoromethyl)phenyl)guanidine;1A-116, 10 mM in DMSO;N-(3,5-Dimethylphenyl)-N'-[2-(trifluoromethyl)phenyl]-guanidine | | CAS: | 1430208-73-3 | | MF: | C16H16F3N3 | | MW: | 307.31 | | EINECS: | | | Product Categories: | API | | Mol File: | 1430208-73-3.mol |  |
| | 1A-116 Chemical Properties |
| Boiling point | 357.5±52.0 °C(Predicted) | | density | 1.22±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 100 mg/mL (325.40 mM);Water : < 0.1 mg/mL (insoluble) | | form | Solid | | pka | 9.78±0.10(Predicted) | | color | White to off-white |
| | 1A-116 Usage And Synthesis |
| Uses | A1-116 is a novel specific Rac1 inhibitor. | | in vivo | 1A-116 (3 mg/kg; i.v.; once a day for 21 days) demonstrates a high antimetastatic activity with about 60% formation reduction of total metastatic lung colonies in vivo and shows no apparent toxicity[1].
1A-116 (20 mg/kg; i.p.; once a day, 73 days for ZT12, 68 days for ZT3) increases survival time when treated at ZT12 compare to ZT3 in tumor-bearing mice. (ZT: Zeitgeber time 12 (ZT12) defined as the time of lights off (local time 7 p.m.) and ZT0 defined as lights on (local time 7 a.m.))[2].
1A-116 shows good oral availability[3]. | Animal Model: | Female BALB/c inbred mice (8 to 10-week-old; average 20 g)[1] | | Dosage: | 3 mg/kg | | Administration: | Intravenous injection; once a day for 21 days. | | Result: | Demonstrated a high antimetastatic activity. |
| Animal Model: | Male NIH Swiss foxN1(/) nude mice (2-month-old; GBM model)[2]. | | Dosage: | 20 mg/kg | | Administration: | Intraperitoneal injection (at ZT3, ZT12); once a day, 73 days for ZT12, 68 days for ZT3. | | Result: | Increased survival time when treated at ZT12 compared to ZT3 in tumor-bearing mice. |
| | storage | Store at -20°C |
| | 1A-116 Preparation Products And Raw materials |
|